Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep 27:8:41-55.
doi: 10.2147/ORR.S85198. eCollection 2016.

Animal models of osteogenesis imperfecta: applications in clinical research

Affiliations
Review

Animal models of osteogenesis imperfecta: applications in clinical research

Tanya A Enderli et al. Orthop Res Rev. .

Abstract

Osteogenesis imperfecta (OI), commonly known as brittle bone disease, is a genetic disease characterized by extreme bone fragility and consequent skeletal deformities. This connective tissue disorder is caused by mutations in the quality and quantity of the collagen that in turn affect the overall mechanical integrity of the bone, increasing its vulnerability to fracture. Animal models of the disease have played a critical role in the understanding of the pathology and causes of OI and in the investigation of a broad range of clinical therapies for the disease. Currently, at least 20 animal models have been officially recognized to represent the phenotype and biochemistry of the 17 different types of OI in humans. These include mice, dogs, and fish. Here, we describe each of the animal models and the type of OI they represent, and present their application in clinical research for treatments of OI, such as drug therapies (ie, bisphosphonates and sclerostin) and mechanical (ie, vibrational) loading. In the future, different dosages and lengths of treatment need to be further investigated on different animal models of OI using potentially promising treatments, such as cellular and chaperone therapies. A combination of therapies may also offer a viable treatment regime to improve bone quality and reduce fragility in animals before being introduced into clinical trials for OI patients.

Keywords: OI; brittle bone; clinical research; dog; mouse; zebrafish.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Similar articles

  • Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
    Sinder BP, White LE, Salemi JD, Ominsky MS, Caird MS, Marini JC, Kozloff KM. Sinder BP, et al. Osteoporos Int. 2014 Aug;25(8):2097-107. doi: 10.1007/s00198-014-2737-y. Epub 2014 May 7. Osteoporos Int. 2014. PMID: 24803333 Free PMC article.
  • Current and Developing Pharmacologic Agents for Improving Skeletal Health in Adults with Osteogenesis Imperfecta.
    Liu W, Nicol L, Orwoll E. Liu W, et al. Calcif Tissue Int. 2024 Mar 12. doi: 10.1007/s00223-024-01188-2. Online ahead of print. Calcif Tissue Int. 2024. PMID: 38472351 Review.
  • An Update on Animal Models of Osteogenesis Imperfecta.
    Lv F, Cai X, Ji L. Lv F, et al. Calcif Tissue Int. 2022 Oct;111(4):345-366. doi: 10.1007/s00223-022-00998-6. Epub 2022 Jun 29. Calcif Tissue Int. 2022. PMID: 35767009 Review.
  • [Osteogenesis imperfecta and achievements in cell and gene therapy].
    Marijanović I, Radnić M, Matić I, Erceg-Ivkosić I. Marijanović I, et al. Acta Med Croatica. 2010 Jul;64(3):191-200. Acta Med Croatica. 2010. PMID: 20922862 Review. Croatian.
  • Osteogenesis Imperfecta.
    Marini JC, Dang Do AN. Marini JC, et al. 2020 Jul 26. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2020 Jul 26. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 25905334 Free Books & Documents. Review.

Cited by

References

    1. Baljet B. Aspects of the history of osteogenesis imperfecta (Vrolik’s syndrome) Ann Anat. 2002;184(1):1–7. - PubMed
    1. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101–116. - PMC - PubMed
    1. Kamoun-Goldrat AS, Le Merrer MF. Animal models of osteogenesis imperfecta and related syndromes. J Bone Miner Metab. 2007;25(4):211–218. - PubMed
    1. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363(9418):1377–1385. - PubMed
    1. Bodian DL, Chan TF, Poon A, et al. Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships. Hum Mol Genet. 2009;18(3):463–471. - PMC - PubMed

LinkOut - more resources